Future Aranesp Discounts Would Respond To Procrit Price Changes, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
First quarter Aranesp pricing adjustments were Amgen’s answer to J&J’s new Procrit clinic contracts. Since the February price changes, Aranesp market share has grown five points, Amgen says.
You may also be interested in...
Procrit Sales Slump Continues Due To 10% Year-Over-Year Price Decline
Conditions, however, are more favorable than in previous quarters due to a June price increase on the EPO brand, J&J says. With prices locked into 12-month contracts, it may take awhile for J&J to reap the full benefit of the price increase.
Procrit Sales Slump Continues Due To 10% Year-Over-Year Price Decline
Conditions, however, are more favorable than in previous quarters due to a June price increase on the EPO brand, J&J says. With prices locked into 12-month contracts, it may take awhile for J&J to reap the full benefit of the price increase.
Price Competition To Procrit Is Beginning To Stabilize, J&J Says
Recent price increases for both Procrit and Amgen’s Aranesp indicate the discount war may be over for now, J&J says. The company remains positive about the impact of the 2005 changes to Medicare Part B drug reimbursement on Procrit’s positioning within the EPO market.